<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Transl Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Transl Psychiatry</journal-id>
<journal-title-group>
<journal-title>Translational Psychiatry</journal-title>
</journal-title-group>
<issn pub-type="epub">2158-3188</issn>
<publisher>
<publisher-name>Nature Publishing Group UK</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30185780</article-id>
<article-id pub-id-type="pmc">6125294</article-id>
<article-id pub-id-type="publisher-id">237</article-id>
<article-id pub-id-type="doi">10.1038/s41398-018-0237-0</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A gene co-expression module implicating the mitochondrial electron transport chain is associated with long-term response to lithium treatment in bipolar affective disorder</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Stacey</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schubert</surname>
<given-names>K. Oliver</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Clark</surname>
<given-names>Scott R.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7940-0335</contrib-id>
<name>
<surname>Amare</surname>
<given-names>Azmeraw T.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Milanesi</surname>
<given-names>Elena</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9559-1725</contrib-id>
<name>
<surname>Maj</surname>
<given-names>Carlo</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Leckband</surname>
<given-names>Susan G.</given-names>
</name>
<xref ref-type="aff" rid="Aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shekhtman</surname>
<given-names>Tatyana</given-names>
</name>
<xref ref-type="aff" rid="Aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kelsoe</surname>
<given-names>John R.</given-names>
</name>
<xref ref-type="aff" rid="Aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9363-1869</contrib-id>
<name>
<surname>Gurwitz</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6548-426X</contrib-id>
<name>
<surname>Baune</surname>
<given-names>Bernhard T.</given-names>
</name>
<address>
<email>bbaune@unimelb.edu.au</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff9">9</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 7304</institution-id><institution-id institution-id-type="GRID">grid.1010.0</institution-id><institution>Discipline of Psychiatry, School of Medicine, </institution><institution>University of Adelaide, </institution></institution-wrap>Adelaide, SA Australia </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000000121885934</institution-id><institution-id institution-id-type="GRID">grid.5335.0</institution-id><institution>MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, </institution><institution>University of Cambridge, </institution></institution-wrap>Cambridge, CB1 8RN UK </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0323 4206</institution-id><institution-id institution-id-type="GRID">grid.460761.2</institution-id><institution>Northern Adelaide Local Health Network, Mental Health Services, Lyell McEwin Hospital, </institution></institution-wrap>Elizabeth Vale, SA 5112 Australia </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.425670.2</institution-id><institution>Genetics Unit, IRCCS, San Giovanni di Dio, Fatebenefratelli, </institution></institution-wrap>Brescia, Italy </aff>
<aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0369 4968</institution-id><institution-id institution-id-type="GRID">grid.433858.1</institution-id><institution>Department of Cellular and Molecular Medicine, </institution><institution>‘Victor Babes’ National Institute of Pathology, </institution></institution-wrap>99-101 Splaiul Independentei, 050096 Bucharest, Romania </aff>
<aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8786 803X</institution-id><institution-id institution-id-type="GRID">grid.15090.3d</institution-id><institution>Institute for Genomic Statistics and Bioinformatics, </institution><institution>University Hospital Bonn, </institution></institution-wrap>Bonn, Germany </aff>
<aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2107 4242</institution-id><institution-id institution-id-type="GRID">grid.266100.3</institution-id><institution>University of California San Diego and VA San Diego Healthcare System, </institution></institution-wrap>San Diego, CA USA </aff>
<aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0546</institution-id><institution-id institution-id-type="GRID">grid.12136.37</institution-id><institution>Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, </institution><institution>Tel Aviv University, </institution></institution-wrap>Tel Aviv, Israel </aff>
<aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2179 088X</institution-id><institution-id institution-id-type="GRID">grid.1008.9</institution-id><institution>Department of Psychiatry, Melbourne Medical School, Royal Melbourne Hospital, </institution><institution>University of Melbourne, </institution></institution-wrap>VIC, Australia </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>5</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>5</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>8</volume>
<elocation-id>183</elocation-id>
<history>
<date date-type="received">
<day>4</day>
<month>1</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>2</day>
<month>6</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>7</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2018</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">Lithium is the first-line treatment for bipolar affective disorder (BPAD) but two-thirds of patients respond only partially or not at all. The reasons for this high variability in lithium response are not well understood. Transcriptome-wide profiling, which tests the interface between genes and the environment, represents a viable means of exploring the molecular mechanisms underlying lithium response variability. Thus, in the present study we performed co-expression network analyses of whole-blood-derived RNA-seq data from <italic>n</italic> = 50 lithium-treated BPAD patients. Lithium response was assessed using the well-validated ALDA scale, which we used to define both a continuous and a dichotomous measure. We identified a nominally significant correlation between a co-expression module comprising 46 genes and lithium response represented as a continuous (i.e., scale ranging 0–10) phenotype (cor = −0.299, <italic>p</italic> = 0.035). Forty-three of these 46 genes had reduced mRNA expression levels in better lithium responders relative to poorer responders, and the central regulators of this module were all mitochondrially-encoded (<italic>MT-ND1</italic>, <italic>MT-ATP6</italic>, <italic>MT-CYB</italic>). Accordingly, enrichment analyses indicated that genes involved in mitochondrial functioning were heavily over-represented in this module, specifically highlighting the electron transport chain (ETC) and oxidative phosphorylation (OXPHOS) as affected processes. Disrupted ETC and OXPHOS activity have previously been implicated in the pathophysiology of BPAD. Our data adds to previous evidence suggesting that a normalisation of these processes could be central to lithium’s mode of action, and could underlie a favourable therapeutic response.</p>
</abstract>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1" sec-type="introduction">
<title>Introduction</title>
<p id="Par2">Bipolar affective disorder (BPAD) affects at least 2% of the population and is characterised by recurring episodes of depression, mania, or mixed affective states<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Mood stabilising medications are prescribed for most BPAD patients. These drugs are effective in ameliorating the symptoms of acute illness episodes<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>, as well as providing long-term protection against episode recurrence<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Lithium is widely considered the ‘gold standard’ mood stabiliser<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref></sup> due to its uniquely protective effects against both manic and depressive episodes<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>, as well as suicide<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. Therefore, lithium is recommended as first-line maintenance treatment for BPAD by several clinical practice guidelines<sup><xref ref-type="bibr" rid="CR7">7</xref>–<xref ref-type="bibr" rid="CR10">10</xref></sup>.</p>
<p id="Par3">However, the clinical response to lithium is highly variable between individuals. While many patients achieve full symptom resolution and long-term recovery, 30% show only partial response, and a further 30% are considered poor responders<sup><xref ref-type="bibr" rid="CR11">11</xref>–<xref ref-type="bibr" rid="CR13">13</xref></sup>. Evidence from the literature highlights some potential clinical predictors of a favourable vs. poor response to lithium in BPAD. These include course of illness, age of BPAD onset, number of BPAD hospitalisations, and pattern of BPAD symptomatology<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>. Further, genetic factors are known to explain some of the clinical variability. ‘Good’ lithium responders are more likely to come from families with a higher prevalence of BPAD, and to have relatives that have also responded favourably<sup><xref ref-type="bibr" rid="CR16">16</xref>–<xref ref-type="bibr" rid="CR18">18</xref></sup>. Previous genetic investigations including linkage<sup><xref ref-type="bibr" rid="CR19">19</xref>–<xref ref-type="bibr" rid="CR21">21</xref></sup>, candidate gene<sup><xref ref-type="bibr" rid="CR22">22</xref>–<xref ref-type="bibr" rid="CR24">24</xref></sup>, and genome-wide association studies (GWAS)<sup><xref ref-type="bibr" rid="CR25">25</xref>–<xref ref-type="bibr" rid="CR27">27</xref></sup> have implicated multiple genes as candidate mediators of the genetic component of lithium response, but the vast majority of these findings have not been replicated<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. Most recently, a GWAS of over 2500 BPAD patients conducted by the International Consortium on Lithium Genetics (ConLi<sup>+</sup>Gen)<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> has implicated an intergenic locus on chromosome 21 at genome-wide significance (<italic>p</italic> &lt; 5 × 10<sup>−08</sup>) for association with a quantitative measure of lithium response. Long intergenic non-coding RNAs (lincRNAs) reside at this locus, suggesting they may mediate this association. However, in-depth follow-up functional characterisation is required before this genome-wide significant association can be harnessed to improve our understanding of the molecular mechanisms underlying the therapeutic effects of lithium, much less provide any clinical utility<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>.</p>
<p id="Par4">No biological markers currently exist in psychiatric practice for the purpose of reliably stratifying subgroups of good vs. poor responders to lithium, at the outset of therapy. This has multiple implications, including the potential risk of prolonging clinical symptoms in patients that are found to respond poorly to lithium and who might otherwise have responded better to an alternative drug. Further, because long-term lithium therapy is associated with potentially serious side effects including chronic renal failure, hypothyroidism and mortality due to acute toxicity<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>, this lack of markers for personalised prescribing puts BPAD patients at additional risk.</p>
<p id="Par5">Transcriptome-wide profiling using microarray or next generation RNA-sequencing technology constitutes a complementary approach towards identifying biological correlates of lithium response in BPAD, with the potential to elucidate the underlying mechanisms. Few such studies to date have been undertaken using patient samples but rather cultured cells that have undergone immortalisation<sup><xref ref-type="bibr" rid="CR30">30</xref>–<xref ref-type="bibr" rid="CR32">32</xref></sup>. Results so far have implicated, for example, apoptotic pathways<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>, neutral amino acid transport<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>, protein ubiquitination, and protein synthesis<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. However, while providing valuable leads for future research, the findings of these studies have been compromised by relatively small sample sizes, associated difficulties with statistical power and multiple testing, and poor replicability<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. Additionally, no previous gene expression study has measured gene expression correlates of long-term response to lithium treatment beyond 6 months.</p>
<p id="Par6">In order to overcome these difficulties in the current study, we performed weighted gene co-expression network analysis (WGCNA), a hypothesis-free systems biology approach that identifies ‘modules’ of co-regulated, and therefore functionally related, genes in transcriptomic data sets. Emerging evidence indicates that such an approach can be advantageous in characterising clinical phenotypes that are highly complex, polygenic, and heterogeneous<sup><xref ref-type="bibr" rid="CR34">34</xref>–<xref ref-type="bibr" rid="CR36">36</xref></sup>, even when utilising transcriptomic data from relatively small sample sizes. Indeed, the recommended minimum sample size to construct a robust network using WGCNA is just 15–20 (<ext-link ext-link-type="uri" xlink:href="https://labs.genetics.ucla.edu/horvath/CoexpressionNetwork/Rpackages/WGCNA/faq.html">https://labs.genetics.ucla.edu/horvath/CoexpressionNetwork/Rpackages/WGCNA/faq.html</ext-link>), while functional term enrichment and pathway analyses have demonstrated that co-expression networks constructed using data from small to moderate sample sizes are biologically meaningful<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup>.</p>
</sec>
<sec id="Sec2" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="Sec3">
<title>Sample recruitment and data collection</title>
<p id="Par7">In all, <italic>n</italic> = 50 BPAD patients of European ancestry (Supplementary Table <xref ref-type="media" rid="MOESM5">1</xref>) undergoing or who had undergone treatment with lithium were recruited from hospitals across the state of South Australia, Australia, as part of the ConLi<sup>+</sup>Gen consortium (<xref ref-type="media" rid="MOESM4">Supplementary Information</xref>)<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> and the ongoing University of Adelaide ‘Cognitive Function and Mood Study’ (CoFaMS, HREC RAH No. 111230). Written informed consent was obtained, after which lithium treatment response data were collected and a 10 mL blood sample was taken by forearm venipuncture into Vacutainer EDTA tubes. Whole-blood samples were then aliquoted into standard Eppendorf tubes; (i) 2 mL aliquots stored at −80 °C for subsequent genomic DNA (gDNA) extraction, and (ii) 1 mL aliquots stabilised with RNA<italic>later</italic>™ (Thermo Fisher Scientific, Norwood SA, Australia) stored at −20 °C for total RNA extraction.</p>
</sec>
<sec id="Sec4">
<title>Measurement of lithium treatment response</title>
<p id="Par8">Lithium treatment response was assessed using a previously published and validated scale called the ‘Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder’ scale, also known as the ALDA scale<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>. The ALDA scale is described in more detail in <xref ref-type="media" rid="MOESM4">Supplementary Information</xref>.</p>
<p id="Par9">For analyses we directly utilised the total ALDA score (i.e., range 0–10) as a ‘continuous’ measure of lithium treatment response, and we also defined a ‘dichotomous’ variable with an ALDA score cutoff ≥ 5 to represent ‘responders’ vs. ‘non-responders’ (<xref ref-type="media" rid="MOESM4">Supplementary Information</xref>).</p>
</sec>
<sec id="Sec5">
<title>Experimental procedures</title>
<sec id="Sec6">
<title>Total RNA purification and quantitation</title>
<p id="Par10">Total RNA was purified from 1 mL human whole blood (stabilised with RNA<italic>later</italic>™ and stored at −80 °C) using the Ambion™ RiboPure™ RNA Purification Kit, blood (Thermo Fisher Scientific, Norwood SA, Australia). Purified total RNA was then immediately quantitated using a Qubit® 2.0 Fluorometer before storage at −80 °C in 1 μg aliquots ready for cDNA library preparation. An additional 10 μL aliquot was also made in order to enable quantification of RNA integrity number (RIN) using the Agilent RNA 6000 Nano Kit and an Agilent 2100 Bioanalyzer.</p>
</sec>
<sec id="Sec7">
<title>cDNA library preparation and RNA sequencing</title>
<p id="Par11">cDNA libraries were prepared with 1 μg total RNA template using the TruSeq Stranded Total RNA with Ribo-Zero Globin kit (Illumina, Scoresby VIC, Australia). Libraries were sequenced using the Illumina HiSeq 4000 in 75 bp paired-end read mode.</p>
</sec>
</sec>
<sec id="Sec8">
<title>Bioinformatics procedures and analyses</title>
<sec id="Sec9">
<title>Processing of RNA sequencing data</title>
<p id="Par12">Basic quality checks were run using FastQC (Andrews: <ext-link ext-link-type="uri" xlink:href="http://www.bioinformatics.babraham.ac.uk/projects/fastqc/">http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link>) followed by adapter and quality (-q option set to 20) trimming with Cutadapt (v1.12) in paired-end mode<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. Remaining reads were pseudoaligned to the human transcriptome (as per GRCh38.84 GTF file downloaded from Ensembl on 08/03/2016) and transcript abundances quantified using Kallisto (v0.44.0)<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. The tximport R package (v1.8.0)<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> was then used to summarise transcript abundances to the gene level.</p>
</sec>
<sec id="Sec10">
<title>Gene co-expression network analysis</title>
<p id="Par13">Gene features with read counts of less than 10 in greater than 90% of samples were first removed and the remaining data were regularised log (rlog) transformed using the DESeq2 R package<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. Residuals after adjusting for age, sex, and RIN were then used as input for weighted gene co-expression network analysis (WGCNA) using the WGCNA R package (1.62)<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> (<xref ref-type="media" rid="MOESM4">Supplementary Information</xref>).</p>
</sec>
<sec id="Sec11">
<title>Enrichment and pathway analyses</title>
<p id="Par14">Functional term and pathway enrichment analyses were performed using the functional annotation clustering tool implemented within the recently updated Database for Annotation, Visualisation, and Integrated Discovery (DAVID) (v6.8)<sup><xref ref-type="bibr" rid="CR44">44</xref></sup> (<xref ref-type="media" rid="MOESM4">Supplementary Information</xref>). For additional exploration of gene networks and canonical pathways associated with lithium response, we used QIAGEN’s Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood City, <ext-link ext-link-type="uri" xlink:href="http://www.qiagen.com/ingenuity">www.qiagen.com/ingenuity</ext-link>).</p>
</sec>
</sec>
</sec>
<sec id="Sec12" sec-type="results">
<title>Results</title>
<sec id="Sec13">
<title>Network construction and prioritisation of a lithium response-associated module</title>
<p id="Par15">We constructed a weighted gene co-expression network using regularised log transformed count data for 13,659 genes from 50 lithium-treated BPAD cases (see methods for details of filtering). The resulting network comprised 23 modules ranging in size between 31 and 2912 genes (Supplementary Fig. <xref ref-type="media" rid="MOESM3">1</xref>).</p>
<p id="Par16">To identify any potential lithium response-relevant modules within our network, we first computed eigengene composite values (<xref ref-type="media" rid="MOESM4">Supplementary Information</xref>)<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> for each module within each of our participants and correlated (Spearman’s rank) them with lithium treatment response scores expressed in both a continuous and dichotomous fashion (see methods). Overall, we found one nominally significant correlation between continuous lithium response and the eigengene of a module denoted ‘royalblue’ (cor = −0.299, <italic>p</italic> = 0.035) (Fig. <xref ref-type="fig" rid="Fig1">1a</xref>). The correlation between this module and dichotomous lithium response did not meet the nominal significance threshold, though the trend was similar (cor = −0.249, <italic>p</italic> = 0.081) (Fig. <xref ref-type="fig" rid="Fig1">1a</xref>). The negative sign on these correlations signifies that the overall expression profile of this module was lower in those participants with higher lithium response scores relative to those with lower scores (Fig. <xref ref-type="fig" rid="Fig1">1a, b</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><title>Identification of a co-expression module relevant for lithium response in BPAD.</title><p><bold>a</bold> Heatmap depicting correlations (<italic>p</italic>-values) between 23 co-expression module eigengenes (MEs) and lithium response represented as a continuous and a dichotomous phenotype. <bold>b</bold> Scatterplot with a line of best fit illustrating the relationship between the royalblue ME and lithium response represented as a continuous phenotype. Colours correspond to different modules from the overall co-expression network. ME module eigengene</p></caption><graphic id="d29e729" xlink:href="41398_2018_237_Fig1_HTML"></graphic></fig></p>
<p id="Par17">In addition, the royalblue module was also significantly correlated with total B scores from the ALDA scale (<xref ref-type="media" rid="MOESM4">Supplementary Information</xref>) (cor = 0.322, <italic>p</italic> = 0.023) (Supplementary Fig. <xref ref-type="media" rid="MOESM2">2a, b</xref>). Notably, there were no additional nominally significant (<italic>p</italic> &lt; 0.05) correlations between the royalblue module and any items from a panel of assessed psychiatric features (Supplementary Fig. <xref ref-type="media" rid="MOESM2">2d</xref>).</p>
</sec>
<sec id="Sec14">
<title>Characterisation of a lithium response-associated module</title>
<p id="Par18">The royalblue module consists of 46 genes in total (Fig. <xref ref-type="fig" rid="Fig2">2</xref>; Supplementary Table <xref ref-type="media" rid="MOESM5">2</xref>); 44 of which are protein-coding while the remaining two encode pseudogenes. A look at the chromosomal distribution of royalblue module genes revealed that 35 are autosomal, 2 reside on the X chromosome, whereas the remaining 9 are all mitochondrially-encoded (Fig. <xref ref-type="fig" rid="Fig2">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><title>Network graph summarising the royalblue co-expression module.</title><p>The royalblue module was visualised according to a prefuse force directed layout based on weighted correlations between genes. Minor manual changes to node placement were made to maximise clarity. The size of each node (and node label) reflects absolute module membership (MM) values, with larger nodes corresponding to higher MM values. Node colour indicates whether royalblue genes were encoded by autosomal (azure), X chromosome (purple), or mitochondrial (red) DNA. Edge width reflects the weighting of connections between nodes, with thicker edges corresponding to stronger connections</p></caption><graphic id="d29e771" xlink:href="41398_2018_237_Fig2_HTML"></graphic></fig></p>
<sec id="Sec15">
<title>Module membership and gene significance</title>
<p id="Par19">In order to identify the central regulators (or hub genes) of the royalblue module, we computed the corresponding module membership (MM) values (see methods). The gene with the highest absolute MM was <italic>MT-ND1</italic> (MM = 0.939, <italic>p</italic> = 7.05E-24) (Table <xref ref-type="table" rid="Tab1">1a</xref>), which encodes the Mitochondrially-Encoded NADH: Ubiquinone Oxidoreductase Core Subunit 1 protein. Further, when we pulled out all genes with a MM &gt; abs(0.8) for inspection (Table <xref ref-type="table" rid="Tab1">1a</xref>), which yielded the top ten genes, the first eight of them were all mitochondrially-encoded, the ninth was an autosomal mitochondrial pseudogene (<italic>MTATP6P1</italic>), whereas the tenth was an autosomal protein-coding gene called <italic>TSPAN9</italic>. Thus, the mitochondrially-encoded genes within the royalblue module are clearly the central regulators (Table <xref ref-type="table" rid="Tab1">1a</xref>; Fig. <xref ref-type="fig" rid="Fig2">2</xref>).<table-wrap id="Tab1"><label>Table 1a</label><caption><p>Top ten genes from the royalblue module with the highest module membership values</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Ensembl ID</th><th>HGNC symbol</th><th>Chr</th><th>Description</th><th>MM</th><th>
<italic>p</italic>
</th><th>GS</th><th>
<italic>p</italic>
</th></tr></thead><tbody><tr><td>ENSG00000198888</td><td>
<italic>MT-ND1</italic>
</td><td>MT</td><td>Mitochondrially-encoded NADH:ubiquinone oxidoreductase core subunit 1</td><td>0.939</td><td>7.05<sup>E-24</sup></td><td>−0.195</td><td>0.174</td></tr><tr><td>ENSG00000198763</td><td>
<italic>MT-ND2</italic>
</td><td>MT</td><td>Mitochondrially-encoded NADH:ubiquinone oxidoreductase core subunit 2</td><td>0.929</td><td>2.04<sup>E-22</sup></td><td>−0.209</td><td>0.145</td></tr><tr><td>ENSG00000198727</td><td>
<italic>MT-CYB</italic>
</td><td>MT</td><td>Mitochondrially-encoded cytochrome b</td><td>0.922</td><td>2.05<sup>E-21</sup></td><td>−0.273</td><td>0.055</td></tr><tr><td>ENSG00000212907</td><td>
<italic>MT-ND4L</italic>
</td><td>MT</td><td>Mitochondrially-encoded NADH:ubiquinone oxidoreductase core subunit 4L</td><td>0.902</td><td>3.87<sup>E-19</sup></td><td>–0.244</td><td>0.087</td></tr><tr><td>ENSG00000198840</td><td>
<italic>MT-ND3</italic>
</td><td>MT</td><td>Mitochondrially-encoded NADH:ubiquinone oxidoreductase core subunit 3</td><td>0.890</td><td>5.40<sup>E-18</sup></td><td>–0.264</td><td>0.064</td></tr><tr><td>ENSG00000198899</td><td>
<italic>MT-ATP6</italic>
</td><td>MT</td><td>Mitochondrially-encoded ATP synthase 6</td><td>0.877</td><td>6.98<sup>E-17</sup></td><td>–0.322</td><td>0.023</td></tr><tr><td>ENSG00000198712</td><td>
<italic>MT-CO2</italic>
</td><td>MT</td><td>Mitochondrially-encoded cytochrome c oxidase II</td><td>0.827</td><td>1.44<sup>E-13</sup></td><td>–0.229</td><td>0.110</td></tr><tr><td>ENSG00000198886</td><td>
<italic>MT-ND4</italic>
</td><td>MT</td><td>Mitochondrially-encoded NADH:ubiquinone oxidoreductase core subunit 4</td><td>0.823</td><td>2.19<sup>E-13</sup></td><td>–0.231</td><td>0.106</td></tr><tr><td>ENSG00000248527</td><td>
<italic>MTATP6P1</italic>
</td><td>1</td><td>Mitochondrially-encoded ATP synthase 6 pseudogene 1</td><td>0.807</td><td>1.43<sup>E-12</sup></td><td>–0.157</td><td>0.276</td></tr><tr><td>ENSG00000011105</td><td>
<italic>TSPAN9</italic>
</td><td>12</td><td>Tetraspanin 9</td><td>0.803</td><td>2.31<sup>E-12</sup></td><td>–0.275</td><td>0.053</td></tr></tbody></table><table-wrap-foot><p>MM module membership to the royalblue module, <italic>GS</italic> gene significance for lithium response represented as a continuous phenotype</p></table-wrap-foot></table-wrap></p>
<p id="Par20">We also computed gene significance (GS) values to determine which individual genes within the royalblue module were most highly correlated with continuous lithium response. The gene with the highest absolute GS was <italic>CPNE5</italic>, which is an autosomal gene encoding a calcium-dependent lipid-binding protein called Copine 5 (GS = −0.416, <italic>p</italic> = 0.003) (Table <xref ref-type="table" rid="Tab2">1b</xref>). Of the ten genes with the highest GS, two of them were mitochondrially-encoded indicating that the apparent mitochondrial-related functioning of the royalblue module is also relevant for its association with lithium response (Table <xref ref-type="table" rid="Tab2">1b</xref>). Accordingly, we observed a small correlation between absolute MM and absolute GS scores for continuous lithium response across the royalblue module, though this did not meet the nominal significance threshold (cor = 0.18, <italic>p</italic> = 0.23) (Supplementary Fig. <xref ref-type="media" rid="MOESM1">3</xref>). Notably, for all but 3 of the 46 royalblue genes (<italic>MARCO</italic>, <italic>AKR1C3</italic>, <italic>PLD4</italic>) the GS values were negatively signed (Supplementary Table <xref ref-type="media" rid="MOESM5">2</xref><bold>)</bold>, which again indicates that the overall expression profile of the royalblue module was downregulated in participants with better lithium response.<table-wrap id="Tab2"><label>Table 1b</label><caption><p>Top ten genes from the royalblue module with the highest gene significance values</p></caption><table frame="hsides" rules="groups"><thead><tr><th>
<bold>Ensembl ID</bold>
</th><th>HGNC symbol</th><th>Chr</th><th>Description</th><th>MM</th><th>
<italic>p</italic>
</th><th>GS</th><th>
<italic>p</italic>
</th></tr></thead><tbody><tr><td>ENSG00000124772</td><td>
<italic>CPNE5</italic>
</td><td>6</td><td>Copine 5</td><td>0.528</td><td>8.22<sup>E-05</sup></td><td>–0.416</td><td>0.003</td></tr><tr><td>ENSG00000102230</td><td>
<italic>PCYT1B</italic>
</td><td>X</td><td>Phosphate cytidylyltransferase 1, choline, beta</td><td>0.777</td><td>3.16<sup>E-11</sup></td><td>–0.341</td><td>0.015</td></tr><tr><td>ENSG00000105808</td><td>
<italic>RASA4</italic>
</td><td>7</td><td>RAS p21 protein activator 4</td><td>0.364</td><td>0.009</td><td>–0.325</td><td>0.021</td></tr><tr><td>ENSG00000165309</td><td>
<italic>ARMC3</italic>
</td><td>10</td><td>Armadillo repeat containing 3</td><td>0.695</td><td>2.22<sup>E-08</sup></td><td>–0.324</td><td>0.022</td></tr><tr><td>ENSG00000198899</td><td>
<italic>MT-ATP6</italic>
</td><td>MT</td><td>Mitochondrially-encoded ATP synthase 6</td><td>0.877</td><td>6.98<sup>E-17</sup></td><td>–0.322</td><td>0.023</td></tr><tr><td>ENSG00000144668</td><td>
<italic>ITGA9</italic>
</td><td>3</td><td>Integrin subunit alpha 9</td><td>0.415</td><td>0.003</td><td>–0.304</td><td>0.032</td></tr><tr><td>ENSG00000137571</td><td>
<italic>SLCO5A1</italic>
</td><td>8</td><td>Solute carrier organic anion transporter family member 5A1</td><td>0.550</td><td>3.45<sup>E-05</sup></td><td>–0.285</td><td>0.045</td></tr><tr><td>ENSG00000136231</td><td>
<italic>IGF2BP3</italic>
</td><td>7</td><td>Insulin like growth factor 2 mRNA binding protein 3</td><td>0.605</td><td>3.26<sup>E-06</sup></td><td>–0.282</td><td>0.047</td></tr><tr><td>ENSG00000011105</td><td>
<italic>TSPAN9</italic>
</td><td>12</td><td>Tetraspanin 9</td><td>0.803</td><td>2.31<sup>E-12</sup></td><td>–0.275</td><td>0.053</td></tr><tr><td>ENSG00000198727</td><td>
<italic>MT-CYB</italic>
</td><td>MT</td><td>Mitochondrially-encoded cytochrome b</td><td>0.922</td><td>2.05<sup>E-21</sup></td><td>–0.273</td><td>0.055</td></tr></tbody></table><table-wrap-foot><p><italic>MM</italic> module membership to the royalblue module, <italic>GS</italic> gene significance for lithium response represented as a continuous phenotype</p></table-wrap-foot></table-wrap></p>
</sec>
<sec id="Sec16">
<title>Term and pathway enrichment analyses</title>
<p id="Par21">In order to functionally characterise the royalblue module we performed term and pathway enrichment analyses using the functional annotation clustering tool available at the Database for Annotation, Visualisation and Integrated Discovery (DAVID) (<xref ref-type="media" rid="MOESM4">Supplementary Information</xref>)<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. Overall, there were two significant functional annotation clusters with an enrichment score &gt; 1.3 (which corresponds to <italic>p</italic> &lt; 0.05) (Fig. <xref ref-type="fig" rid="Fig3">3</xref>; Supplementary Table <xref ref-type="media" rid="MOESM5">3</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><title>Enrichment analyses of royalblue module genes.</title><p>Bar charts summarising two significant functional annotation clusters indicating enrichment of <bold>a</bold> mitochondrial-related genes and <bold>b</bold> genes encoding membrane proteins. Fold enrichment of individual terms within each cluster is indicated by bar length, and corresponding uncorrected <italic>p</italic>-values are indicated to the right of each bar. Note the difference in fold enrichment scale between <bold>a</bold> and <bold>b</bold> panels. UP uniProt, KEGG kyoto encyclopaedia of genes and genomes, EC enzyme commission, GO gene ontology, MF molecular function, BP biological process, CC cellular component, IntAct molecular interaction database, SEQ sequence annotation</p></caption><graphic id="d29e1596" xlink:href="41398_2018_237_Fig3_HTML"></graphic></fig></p>
<p id="Par22">The top cluster, which had an enrichment score of 4.1, consisted of 33 annotation terms and was driven primarily by the mitochondrially-encoded genes within the module. Among the top annotation terms within this cluster were multiple mitochondrial-related Uniprot keywords including ‘Respiratory chain’ (32-fold enrichment), ‘Ubiquinone’ (51-fold), and ‘Electron transport’ (20-fold); while the top functional pathways include ‘Oxidative phosphorylation’ (16-fold) (KEGG; hsa00190) and ‘Respiratory electron transport’ (21-fold) (Reactome; R-HSA-611105) (Fig. <xref ref-type="fig" rid="Fig3">3a</xref>; Supplementary Table <xref ref-type="media" rid="MOESM5">3</xref>). Of particular note, there was also a gene ontology (GO) cellular component (CC) term specifically highlighting complex I of the respiratory chain (29-fold), which was associated with five paralogous royalblue mitochondrially-encoded genes (<italic>MT-ND1</italic>, <italic>2</italic>, <italic>3</italic>, <italic>4</italic>, and <italic>4L</italic>).</p>
<p id="Par23">The second functional annotation cluster had an enrichment score of 2.6 and was composed of five annotation terms in total, all of which indicate a general overrepresentation of royalblue-encoded proteins localised to membranes. The fold-enrichments here were much more subtle, with a range between 1.5- and 2.2-fold. Notably, the mitochondrially-encoded genes did contribute towards these enrichments though they were not the main drivers (Fig. <xref ref-type="fig" rid="Fig3">3b</xref>; Supplementary Table <xref ref-type="media" rid="MOESM5">3</xref>).</p>
<p id="Par24">To further explore and validate these functional findings, we subjected the royalblue module to Ingenuity® Pathway Analysis (IPA®). Canonical pathway analysis confirmed the centrality of mitochondrial mechanisms to the module, and listed ‘oxidative phosphorylation’ (<italic>p</italic> = 7.16E-13, 8.3% pathway overlap) and ‘mitochondrial dysfunction’ (4.28E-11, 5.3% pathway overlap) as top hits (supplementary Table <xref ref-type="media" rid="MOESM5">4</xref>). IPA® analysis of functional networks revealed as top hit a network with the annotations ‘metabolic disease, developmental disorder, hereditary disorder’. This network achieved an IPA® network score of 35, indicating that the overlap between this network and the royalblue module genes is highly significant (i.e., an IPA® network score of &gt; 2 corresponds to <italic>p</italic> &lt; 0.01). Visualisation of this network identified the downregulation of mitochondrial complex 1 as the central functional hub within the royalblue module (Fig. <xref ref-type="fig" rid="Fig4">4</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><title>Graphic representation of the IPA® top gene network derived from the royalblue module.</title><p>Green colour indicates reduced gene expression in better lithium treatment responders, relative to poor responders. Red colour indicates increased gene expression, respectively. The mitochondrial complex 1 is identified as the central functional hub within the royalblue module</p></caption><graphic id="d29e1653" xlink:href="41398_2018_237_Fig4_HTML"></graphic></fig></p>
</sec>
</sec>
</sec>
<sec id="Sec17" sec-type="discussion">
<title>Discussion</title>
<p id="Par25">To identify biological systems and mechanisms associated with lithium response in BPAD, we performed co-expression network analyses of whole-blood-derived RNA sequence data from <italic>n</italic> = 50 BPAD cases with lithium response data. We identified a module (denoted ‘royalblue’) comprising 46 genes that was negatively correlated, at nominal significance, with lithium response represented as a continuous phenotype. Functional characterisation of this module by term enrichment and pathway analyses revealed that its central regulators (9 out of 46 genes) are mitochondrially-derived, and encode components of the electron transport chain (ETC) and oxidative phosphorylation (OXPHOS) pathway. These mechanisms fulfil multiple roles, chief among them being the production of adenosine triphosphate (ATP), the cell’s primary source of chemical energy<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup>.</p>
<p id="Par26">Reassuringly, the findings from our study are in keeping with previous literature relating to BPAD and lithium response. Firstly, numerous gene expression studies in both peripheral and central tissues have already shown altered mRNA levels of multiple mitochondrial-related genes in BPAD patients relative to controls<sup><xref ref-type="bibr" rid="CR47">47</xref>–<xref ref-type="bibr" rid="CR49">49</xref></sup>. This includes a number of the mitochondrially-encoded genes found to be altered in the present study such as <italic>MT-ND2</italic> and <italic>MT-ATP6</italic> among others. Secondly, in addition to evidence from gene expression studies, there are many other lines of evidence ranging from post-mortem, genetic, brain imaging, peripheral cell, and animal studies that point to general mitochondrial dysfunction in the pathophysiology of BPAD<sup><xref ref-type="bibr" rid="CR50">50</xref>–<xref ref-type="bibr" rid="CR52">52</xref></sup>. And thirdly, lithium treatment has been shown on multiple occasions to impact mitochondrial functioning, at least in part by modulating ETC and OXPHOS pathway activity<sup><xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR54">54</xref></sup>.</p>
<p id="Par27">Of particular note is a recent landmark study that generated dentate gyrus (DG) granule cell-like neurons using induced pluripotent stem cells (iPSCs) collected from six BPAD patients and four healthy controls<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. RNA-seq analyses of these cells highlighted 45 genes as being significantly (FDR &lt; 0.1) differentially expressed between patients and controls, which included six mitochondrially-encoded transfer RNAs that were all enhanced in BPAD neurons. In accordance with this, the authors observed enhanced mitochondrial membrane potential (MMP) in BPAD DG-like neurons, which is indicative of increased mitochondrial functioning.</p>
<p id="Par28">Crucially, the BPAD patients from this study were selected based on their known response to lithium treatment; three ‘lithium responders’ (LR) and three ‘non-responders’ (NR)<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. Following chronic lithium treatment, RNA-seq analyses revealed 560 differentially expressed genes in LR DG-like neurons relative to control, compared to just 40 genes from the NR group. Further, 84 of these differentially expressed genes from the LR group were found to have been rescued by lithium treatment, including ten mitochondrially-encoded genes that were downregulated in response to chronic lithium. Strikingly, 7 of these 10 mitochondrial genes belong to the royalblue module identified in the present study, all of which we found had lower mRNA expression in better lithium responders relative to poorer.</p>
<p id="Par29">Thus, the directionality observed in whole blood in our study with regards to mitochondrially-encoded gene expression is consistent with that previously seen in DG-like neurons derived from iPSCs<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. This consistency offers convincing support for the validity and robustness of our findings, which is underscored not only by the obvious difference between the two studies in terms of tissue, but also the difference in phenotype definition. Indeed, in our study we utilised the ALDA scale to define lithium response both as a continuous and a dichotomous variable, where we observed a nominally significant association with the continuous phenotype only. In contrast, the iPSC study used the Clinical Global Impressions Scale to define a dichotomous phenotype; i.e., LR vs. NR<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. However, it is important to note that only two BPAD patients in our study achieved a total ALDA score ≥ 7, which according to ConLi<sup>+</sup>Gen is the optimum cutoff to define a dichotomous phenotype<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. We, therefore, used a lower cutoff of 5 (<xref ref-type="media" rid="MOESM4">Supplementary Information</xref>), which may explain why we did not observe a significant correlation with our dichotomous phenotype.</p>
<p id="Par30">Nevertheless, given there is ample precedence for a relationship between mitochondrial functioning, BPAD, and lithium response, one of the major questions going forward is to determine the precise mechanisms underlying this relationship. One intriguing line of investigation points to a possible mediating role for neuronal excitability. Previous studies have reported hyperexcitable neurons within the VTA and DG of animal models of BPAD, which is considered to be a potential endophenotype of BPAD in humans<sup><xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR57">57</xref></sup>. In the aforementioned iPSC study, patch-clamp recordings revealed that iPSC-derived DG-like neurons from BPAD patients are indeed hyperexcitable relative to healthy control neurons<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. Furthermore, they also showed that this phenotype could be selectively rescued by chronic lithium treatment; though intriguingly this effect was only observed in the LR neurons, not the NR neurons. Given the authors observed this exact same pattern with regards to mitochondrially-encoded mRNA expression<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>, this suggests mitochondrial functioning and neuronal excitability in DG-like neurons could be intimately linked, and may act synergistically to modulate lithium response in BPAD.</p>
<p id="Par31">Although this proposed link is circumstantial at present, it does make intuitive sense given that neuronal excitability is inherently dependent on ATP produced by the ETC and OXPHOS pathways. It is noteworthy that in a follow-up study using an independent sample of iPSCs, the authors observed subtle differences in electrophysiological measures between LR and NR DG-like neurons<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>, indicating that the mechanisms driving neuronal hyperexcitability in these two groups of BPAD patients may be distinct. Strikingly, the authors were able to use these electrophysiological differences in DG-like neurons to predict the responsiveness of a new patient to lithium with a success rate of over 92%. Thus, if the proposed links between hyperexcitability, mitochondrial functioning, and lithium responsiveness support the notion of a discrete lithium-responsive phenotype, this inspires genuine hope for the future of personalised medicine in BPAD, particularly if the underlying mitochondrial dysregulation can be detected in the periphery as findings from the present study suggest.</p>
<p id="Par32">Nevertheless, as a first priority the correlation observed in the present study between the royalblue module and lithium response requires replication, preferably in a larger independent sample of BPAD patients. To the best of our knowledge a genuine ‘like-for-like’ independent replication sample with whole-blood transcriptomic data is not currently available, and so we urge future studies to address this gap. The closest replication sample we were able to find, albeit with a smaller sample size, comprised of RNA-seq data from cultured lymphoblastoid cell lines (LCLs) derived from 24 BPAD patients; 12 LRs (total ALDA ≥ 7) and 12 NRs (total ALDA &lt; 7). We note that we were unable to replicate our findings in this independent sample using either a dichotomous or a continuous phenotype definition (data not shown). However, the core mitochondrial genes of the royalblue module did not survive the filtering process in this data set, rendering replication unlikely, and so given the clear differences between this sample (in vitro) and ours (ex vivo), we believe further replication attempts in more comparable samples are necessary.</p>
<p id="Par33">We also urge comprehensive functional validation in future independent replication samples to determine the downstream effects of royalblue module dysregulation at the mRNA level. For example, is lithium response significantly correlated with the royalblue module at the protein level as measured in serum or plasma? Even further downstream than this, we suggest metabolic measures to capture ETC and OXPHOS activity, along with MMP and mitochondrial morphology, should feature on a panel of mitochondrial phenotypes for comparison between better and poorer lithium responders. As already alluded to, findings from these types of assays could prove to be vital for informing the development of mitochondrial biomarkers to help predict lithium response in BPAD.</p>
<p id="Par34">A major limitation of the present study relates to the cause-effect conundrum that plagues gene expression studies in general. This issue is further compounded in our case by the retrospective nature of our lithium treatment response measure. For example, the measure cannot ultimately distinguish lithium effects from mechanisms underlying spontaneous remission from BPAD episodes, which have been described extensively in the historic literature<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>. It is not possible to disentangle this issue based on these data alone, though genetic association data can provide useful information. Although mitochondrial DNA variation has so far received little attention in relation to lithium response in BPAD, there has been a report of a significant association between the mtDNA 10398A polymorphism and lithium response<sup><xref ref-type="bibr" rid="CR60">60</xref></sup>. This polymorphism results in an amino acid substitution in <italic>MT-ND3</italic>, which is one of the mitochondrially-encoded genes comprising the royalblue module. Thus, future work is required to determine whether the regulation of the royalblue module may in fact be driven by mtDNA polymorphism.</p>
<p id="Par35">To conclude, in the present study we highlight a peripheral blood co-expression module comprising 46 genes that may be of relevance for lithium treatment response in BPAD patients. This module is heavily enriched with mitochondrial-related genes involved primarily in the ETC and OXPHOS, and the expression of these genes was found to be lower in better lithium responders relative to poorer. Importantly, our findings are pre-validated by previous transcriptomic studies supportive of an association not only between mitochondrially-encoded mRNA expression levels and BPAD, but also lithium response in BPAD. Furthermore, the apparent dysregulation of the royalblue module observed here is subtle, which speaks to the sensitivity of co-expression network analysis approaches while underscoring the importance of complementing traditional SNP- and gene-centric approaches with systems biology methodology.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Electronic supplementary material</title>
<sec id="Sec19">
<p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41398_2018_237_MOESM1_ESM.pdf"><caption><p>Suppl fig 3</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41398_2018_237_MOESM2_ESM.pdf"><caption><p>Suppl fig 2</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41398_2018_237_MOESM3_ESM.pdf"><caption><p>Suppl fig 1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="41398_2018_237_MOESM4_ESM.docx"><caption><p>Suppl information</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="41398_2018_237_MOESM5_ESM.xlsx"><caption><p>suppl tables</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="41398_2018_237_MOESM6_ESM.docx"><caption><p>Supplemental Legends</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn>
<p><bold>Publisher's note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
</fn-group>
<sec>
<title>Electronic supplementary material</title>
<p><bold>Supplementary Information</bold> accompanies this paper at (10.1038/s41398-018-0237-0).</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>This work was supported by a Clinical Project Grant (#1997) awarded to D.S., S.R.C., and B.T.B. by the Royal Adelaide Hospital Research Foundation. D.G. and J.R.K. were supported by the US Israel Binational Science Foundation (BSF; Grant No. 2013223). J.R.K. was also supported by the NIMH (U01 MH92758) and US Department of Veterans Affairs.</p>
</ack>
<notes notes-type="COI-statement">
<sec id="FPar1">
<title>Conflict of interest</title>
<p>The authors declare that they have no conflict of interest.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tighe</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Mahon</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Potash</surname>
<given-names>JB</given-names>
</name>
</person-group>
<article-title>Predictors of lithium response in bipolar disorder</article-title>
<source/>Ther. Adv. Chronic Dis.
          <year>2011</year>
<volume>2</volume>
<fpage>209</fpage>
<lpage>226</lpage>
<pub-id pub-id-type="doi">10.1177/2040622311399173</pub-id>
<pub-id pub-id-type="pmid">23251751</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yildiz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vieta</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Leucht</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials</article-title>
<source/>Neuropsychopharmacology
          <year>2011</year>
<volume>36</volume>
<fpage>375</fpage>
<lpage>389</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2010.192</pub-id>
<pub-id pub-id-type="pmid">20980991</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miura</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis</article-title>
<source/>Lancet Psychiatry
          <year>2014</year>
<volume>1</volume>
<fpage>351</fpage>
<lpage>359</lpage>
<pub-id pub-id-type="doi">10.1016/S2215-0366(14)70314-1</pub-id>
<pub-id pub-id-type="pmid">26360999</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malhi</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Tanious</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Berk</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The science and practice of lithium therapy</article-title>
<source/>Aust. N. Z. J. Psychiatry
          <year>2012</year>
<volume>46</volume>
<fpage>192</fpage>
<lpage>211</lpage>
<pub-id pub-id-type="doi">10.1177/0004867412437346</pub-id>
<pub-id pub-id-type="pmid">22391277</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malhi</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Berk</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Is lithium in a class of its own? A brief profile of its clinical use</article-title>
<source/>Aust. N. Z. J. Psychiatry
          <year>2009</year>
<volume>43</volume>
<fpage>1096</fpage>
<lpage>1104</lpage>
<pub-id pub-id-type="doi">10.3109/00048670903279937</pub-id>
<pub-id pub-id-type="pmid">20001408</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tondo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hennen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis</article-title>
<source/>Acta Psychiatr. Scand.
          <year>2001</year>
<volume>104</volume>
<fpage>163</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="doi">10.1034/j.1600-0447.2001.00464.x</pub-id>
<pub-id pub-id-type="pmid">11531653</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<mixed-citation publication-type="other">NICE. Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care. <italic>NICE</italic> Leicester (UK), 2006.</mixed-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yatham</surname>
<given-names>LN</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013</article-title>
<source/>Bipolar Disord.
          <year>2013</year>
<volume>15</volume>
<fpage>1</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1111/bdi.12025</pub-id>
<pub-id pub-id-type="pmid">23237061</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malhi</surname>
<given-names>GS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders</article-title>
<source/>Aust. N. Z. J. Psychiatry
          <year>2015</year>
<volume>49</volume>
<fpage>1087</fpage>
<lpage>1206</lpage>
<pub-id pub-id-type="doi">10.1177/0004867415617657</pub-id>
<pub-id pub-id-type="pmid">26643054</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodwin</surname>
<given-names>GM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology</article-title>
<source/>J. Psychopharmacol.
          <year>2016</year>
<volume>30</volume>
<fpage>495</fpage>
<lpage>553</lpage>
<pub-id pub-id-type="doi">10.1177/0269881116636545</pub-id>
<pub-id pub-id-type="pmid">26979387</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baldessarini</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Tondo</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Does lithium treatment still work? Evidence of stable responses over three decades</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2000</year>
<volume>57</volume>
<fpage>187</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.57.2.187</pub-id>
<pub-id pub-id-type="pmid">10665622</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rybakowski</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Chlopocka-Wozniak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Suwalska</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The prophylactic effect of long-term lithium administration in bipolar patients entering treatment in the 1970s and 1980s</article-title>
<source/>Bipolar Disord.
          <year>2001</year>
<volume>3</volume>
<fpage>63</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1034/j.1399-5618.2001.030203.x</pub-id>
<pub-id pub-id-type="pmid">11333064</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garnham</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study</article-title>
<source/>J. Affect Disord.
          <year>2007</year>
<volume>104</volume>
<fpage>185</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2007.03.003</pub-id>
<pub-id pub-id-type="pmid">17442400</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rybakowski</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Response to lithium in bipolar disorder: Clinical and genetic findings</article-title>
<source/>ACS Chem. Neurosci.
          <year>2014</year>
<volume>5</volume>
<fpage>413</fpage>
<lpage>421</lpage>
<pub-id pub-id-type="doi">10.1021/cn5000277</pub-id>
<pub-id pub-id-type="pmid">24625017</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kleindienst</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Greil</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders</article-title>
<source/>Bipolar Disord.
          <year>2005</year>
<volume>7</volume>
<fpage>404</fpage>
<lpage>417</lpage>
<pub-id pub-id-type="doi">10.1111/j.1399-5618.2005.00244.x</pub-id>
<pub-id pub-id-type="pmid">16176433</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duffy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Alda</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Milin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Grof</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>A consecutive series of treated affected offspring of parents with bipolar disorder: is response associated with the clinical profile?</article-title>
<source/>Can. J. Psychiatry
          <year>2007</year>
<volume>52</volume>
<fpage>369</fpage>
<lpage>376</lpage>
<pub-id pub-id-type="doi">10.1177/070674370705200606</pub-id>
<pub-id pub-id-type="pmid">17696023</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grof</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Is response to prophylactic lithium a familial trait?</article-title>
<source/>J. Clin. Psychiatry
          <year>2002</year>
<volume>63</volume>
<fpage>942</fpage>
<lpage>947</lpage>
<pub-id pub-id-type="doi">10.4088/JCP.v63n1013</pub-id>
<pub-id pub-id-type="pmid">12416605</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mendlewicz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Verbanck</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Linkowski</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wilmotte</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Lithium accumulation in erythrocytes of manic-depressive patients: an in vivo twin study</article-title>
<source/>Br. J. Psychiatry
          <year>1978</year>
<volume>133</volume>
<fpage>436</fpage>
<lpage>444</lpage>
<pub-id pub-id-type="doi">10.1192/bjp.133.5.436</pub-id>
<pub-id pub-id-type="pmid">569523</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turecki</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lithium responsive bipolar disorder, unilineality, and chromosome 18: A linkage study</article-title>
<source/>Am. J. Med. Genet.
          <year>1999</year>
<volume>88</volume>
<fpage>411</fpage>
<lpage>415</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(19990820)88:4&lt;411::AID-AJMG20&gt;3.0.CO;2-9</pub-id>
<pub-id pub-id-type="pmid">10402510</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turecki</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium</article-title>
<source/>Mol. Psychiatry
          <year>2001</year>
<volume>6</volume>
<fpage>570</fpage>
<lpage>578</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4000888</pub-id>
<pub-id pub-id-type="pmid">11526471</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopez de Lara</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Implication of synapse-related genes in bipolar disorder by linkage and gene expression analyses</article-title>
<source/>Int. J. Neuropsychopharmacol. / Off. Sci. J. Coll. Int. Neuropsychopharmacol.
          <year>2010</year>
<volume>13</volume>
<fpage>1397</fpage>
<lpage>1410</lpage>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sjoholt</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Examination of IMPA1 and IMPA2 genes in manic-depressive patients: association between IMPA2 promoter polymorphisms and bipolar disorder</article-title>
<source/>Mol. Psychiatry
          <year>2004</year>
<volume>9</volume>
<fpage>621</fpage>
<lpage>629</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4001460</pub-id>
<pub-id pub-id-type="pmid">14699425</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serretti</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Serotonin transporter gene (5-HTTLPR) and major psychoses</article-title>
<source/>Mol. Psychiatry
          <year>2002</year>
<volume>7</volume>
<fpage>95</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4000936</pub-id>
<pub-id pub-id-type="pmid">11803453</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adli</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism</article-title>
<source/>Biol. Psychiatry
          <year>2007</year>
<volume>62</volume>
<fpage>1295</fpage>
<lpage>1302</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2007.03.023</pub-id>
<pub-id pub-id-type="pmid">17628506</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perlis</surname>
<given-names>RH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder</article-title>
<source/>Am. J. Psychiatry
          <year>2009</year>
<volume>166</volume>
<fpage>718</fpage>
<lpage>725</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.2009.08111633</pub-id>
<pub-id pub-id-type="pmid">19448189</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Squassina</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder</article-title>
<source/>Pharmacogenomics
          <year>2011</year>
<volume>12</volume>
<fpage>1559</fpage>
<lpage>1569</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.11.102</pub-id>
<pub-id pub-id-type="pmid">21961650</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>CH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Variant GADL1 and response to lithium therapy in bipolar I disorder</article-title>
<source/>N. Engl. J. Med.
          <year>2014</year>
<volume>370</volume>
<fpage>119</fpage>
<lpage>128</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1212444</pub-id>
<pub-id pub-id-type="pmid">24369049</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Can</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schulze</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Gould</surname>
<given-names>TD</given-names>
</name>
</person-group>
<article-title>Molecular actions and clinical pharmacogenetics of lithium therapy</article-title>
<source/>Pharmacol. Biochem. Behav.
          <year>2014</year>
<volume>123</volume>
<fpage>3</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1016/j.pbb.2014.02.004</pub-id>
<pub-id pub-id-type="pmid">24534415</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study</article-title>
<source/>Lancet
          <year>2016</year>
<volume>387</volume>
<fpage>1085</fpage>
<lpage>1093</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(16)00143-4</pub-id>
<pub-id pub-id-type="pmid">26806518</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beech</surname>
<given-names>RD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gene-expression differences in peripheral blood between lithium responders and non-responders in the Lithium Treatment-Moderate dose Use Study (LiTMUS)</article-title>
<source/>Pharm. J.
          <year>2014</year>
<volume>14</volume>
<fpage>182</fpage>
<lpage>191</lpage>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lowthert</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased ratio of anti-apoptotic to pro-apoptotic Bcl2 gene-family members in lithium-responders one month after treatment initiation</article-title>
<source/>Biol. Mood Anxiety Disord.
          <year>2012</year>
<volume>2</volume>
<fpage>15</fpage>
<pub-id pub-id-type="doi">10.1186/2045-5380-2-15</pub-id>
<pub-id pub-id-type="pmid">22967286</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anand</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of lithium monotherapy for bipolar disorder on gene expression in peripheral lymphocytes</article-title>
<source/>Mol. Neuropsychiatry
          <year>2016</year>
<volume>2</volume>
<fpage>115</fpage>
<lpage>123</lpage>
<pub-id pub-id-type="doi">10.1159/000446348</pub-id>
<pub-id pub-id-type="pmid">27867936</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alda</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics</article-title>
<source/>Mol. Psychiatry
          <year>2015</year>
<volume>20</volume>
<fpage>661</fpage>
<lpage>670</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2015.4</pub-id>
<pub-id pub-id-type="pmid">25687772</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Langfelder</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Horvath</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>WGCNA: an R package for weighted correlation network analysis</article-title>
<source/>BMC Bioinforma.
          <year>2008</year>
<volume>9</volume>
<fpage>559</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2105-9-559</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Langfelder</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Horvath</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Eigengene networks for studying the relationships between co-expression modules</article-title>
<source/>BMC Syst. Biol.
          <year>2007</year>
<volume>1</volume>
<fpage>54</fpage>
<pub-id pub-id-type="doi">10.1186/1752-0509-1-54</pub-id>
<pub-id pub-id-type="pmid">18031580</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parikshak</surname>
<given-names>NN</given-names>
</name>
<name>
<surname>Gandal</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Geschwind</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>Systems biology and gene networks in neurodevelopmental and neurodegenerative disorders</article-title>
<source/>Nat. Rev. Genet.
          <year>2015</year>
<volume>16</volume>
<fpage>441</fpage>
<lpage>458</lpage>
<pub-id pub-id-type="doi">10.1038/nrg3934</pub-id>
<pub-id pub-id-type="pmid">26149713</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voineagu</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Transcriptomic analysis of autistic brain reveals convergent molecular pathology</article-title>
<source/>Nature
          <year>2011</year>
<volume>474</volume>
<fpage>380</fpage>
<lpage>384</lpage>
<pub-id pub-id-type="doi">10.1038/nature10110</pub-id>
<pub-id pub-id-type="pmid">21614001</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<mixed-citation publication-type="other">Schubert, K. O.et al. Targeted proteomic analysis of cognitive dysfunction in remitted major depressive disorder: Opportunities of multi-omics approaches towards predictive, preventive, and personalized psychiatry. J. Proteom. (2018).</mixed-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manchia</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Assessment of response to lithium maintenance treatment in bipolar disorder: A Consortium on Lithium Genetics (ConLiGen) Report</article-title>
<source/>PLoS ONE
          <year>2013</year>
<volume>8</volume>
<fpage>e65636</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0065636</pub-id>
<pub-id pub-id-type="pmid">23840348</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<mixed-citation publication-type="other">Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. <bold>17</bold>, 10–12 (2011).</mixed-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bray</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>Pimentel</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Melsted</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pachter</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Near-optimal probabilistic RNA-seq quantification</article-title>
<source/>Nat. Biotechnol.
          <year>2016</year>
<volume>34</volume>
<fpage>525</fpage>
<lpage>527</lpage>
<pub-id pub-id-type="doi">10.1038/nbt.3519</pub-id>
<pub-id pub-id-type="pmid">27043002</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soneson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Love</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>MD</given-names>
</name>
</person-group>
<article-title>Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences</article-title>
<source/>F1000Res.
          <year>2015</year>
<volume>4</volume>
<fpage>1521</fpage>
<pub-id pub-id-type="doi">10.12688/f1000research.7563.1</pub-id>
<pub-id pub-id-type="pmid">26925227</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Love</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Anders</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>
<source/>Genome Biol.
          <year>2014</year>
<volume>15</volume>
<fpage>550</fpage>
<pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id>
<pub-id pub-id-type="pmid">25516281</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang da</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Sherman</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Lempicki</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title>
<source/>Nat. Protoc.
          <year>2009</year>
<volume>4</volume>
<fpage>44</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.1038/nprot.2008.211</pub-id>
<pub-id pub-id-type="pmid">19131956</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Revealing various coupling of electron transfer and proton pumping in mitochondrial respiratory chain</article-title>
<source/>Curr. Opin. Struct. Biol.
          <year>2013</year>
<volume>23</volume>
<fpage>526</fpage>
<lpage>538</lpage>
<pub-id pub-id-type="doi">10.1016/j.sbi.2013.06.013</pub-id>
<pub-id pub-id-type="pmid">23867107</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jonckheere</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Smeitink</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Rodenburg</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Mitochondrial ATP synthase: architecture, function and pathology</article-title>
<source/>J. Inherit. Metab. Dis.
          <year>2012</year>
<volume>35</volume>
<fpage>211</fpage>
<lpage>225</lpage>
<pub-id pub-id-type="doi">10.1007/s10545-011-9382-9</pub-id>
<pub-id pub-id-type="pmid">21874297</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beech</surname>
<given-names>RD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased peripheral blood expression of electron transport chain genes in bipolar depression</article-title>
<source/>Bipolar Disord.
          <year>2010</year>
<volume>12</volume>
<fpage>813</fpage>
<lpage>824</lpage>
<pub-id pub-id-type="doi">10.1111/j.1399-5618.2010.00882.x</pub-id>
<pub-id pub-id-type="pmid">21176028</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naydenov</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>MacDonald</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Ongur</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Konradi</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Differences in lymphocyte electron transport gene expression levels between subjects with bipolar disorder and normal controls in response to glucose deprivation stress</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2007</year>
<volume>64</volume>
<fpage>555</fpage>
<lpage>564</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.64.5.555</pub-id>
<pub-id pub-id-type="pmid">17485607</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>LT</given-names>
</name>
</person-group>
<article-title>Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder</article-title>
<source/>J. Psychiatry Neurosci.: JPN
          <year>2006</year>
<volume>31</volume>
<fpage>189</fpage>
<lpage>196</lpage>
<pub-id pub-id-type="pmid">16699605</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moretti</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tamoxifen effects on respiratory chain complexes and creatine kinase activities in an animal model of mania</article-title>
<source/>Pharmacol. Biochem. Behav.
          <year>2011</year>
<volume>98</volume>
<fpage>304</fpage>
<lpage>310</lpage>
<pub-id pub-id-type="doi">10.1016/j.pbb.2011.01.017</pub-id>
<pub-id pub-id-type="pmid">21281661</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andreazza</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>LT</given-names>
</name>
</person-group>
<article-title>Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2010</year>
<volume>67</volume>
<fpage>360</fpage>
<lpage>368</lpage>
<pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2010.22</pub-id>
<pub-id pub-id-type="pmid">20368511</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Sousa</surname>
<given-names>RT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Leukocyte mitochondrial DNA copy number in bipolar disorder</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2014</year>
<volume>48</volume>
<fpage>32</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2013.09.002</pub-id>
<pub-id pub-id-type="pmid">24036318</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Sousa</surname>
<given-names>RT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lithium increases leukocyte mitochondrial complex I activity in bipolar disorder during depressive episodes</article-title>
<source/>Psychopharmacol. (Berl.)
          <year>2015</year>
<volume>232</volume>
<fpage>245</fpage>
<lpage>250</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-014-3655-6</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maurer</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Schippel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Volz</surname>
<given-names>HP</given-names>
</name>
</person-group>
<article-title>Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue</article-title>
<source/>Bipolar Disord.
          <year>2009</year>
<volume>11</volume>
<fpage>515</fpage>
<lpage>522</lpage>
<pub-id pub-id-type="doi">10.1111/j.1399-5618.2009.00729.x</pub-id>
<pub-id pub-id-type="pmid">19624390</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mertens</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder</article-title>
<source/>Nature
          <year>2015</year>
<volume>527</volume>
<fpage>95</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="doi">10.1038/nature15526</pub-id>
<pub-id pub-id-type="pmid">26524527</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coque</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Specific role of VTA dopamine neuronal firing rates and morphology in the reversal of anxiety-related, but not depression-related behavior in the ClockDelta19 mouse model of mania</article-title>
<source/>Neuropsychopharmacology
          <year>2011</year>
<volume>36</volume>
<fpage>1478</fpage>
<lpage>1488</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2011.33</pub-id>
<pub-id pub-id-type="pmid">21430648</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagihara</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Takao</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Walton</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Miyakawa</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Immature dentate gyrus: an endophenotype of neuropsychiatric disorders</article-title>
<source/>Neural Plast.
          <year>2013</year>
<volume>2013</volume>
<fpage>318596</fpage>
<pub-id pub-id-type="doi">10.1155/2013/318596</pub-id>
<pub-id pub-id-type="pmid">23840971</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<mixed-citation publication-type="other">Stern S., et al. Neurons derived from patients with bipolar disorder divide into intrinsically different sub-populations of neurons, predicting the patients’ responsiveness to lithium. <italic>Mol. Psychiatry</italic> 1453–1465 2017.</mixed-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Angst</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sellaro</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Historical perspectives and natural history of bipolar disorder</article-title>
<source/>Biol. Psychiatry
          <year>2000</year>
<volume>48</volume>
<fpage>445</fpage>
<lpage>457</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-3223(00)00909-4</pub-id>
<pub-id pub-id-type="pmid">11018218</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Washizuka</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Possible relationship between mitochondrial DNA polymorphisms and lithium response in bipolar disorder</article-title>
<source/>Int. J. Neuropsychopharmacol. / Off. Sci. J. Coll. Int. Neuropsychopharmacol.
          <year>2003</year>
<volume>6</volume>
<fpage>421</fpage>
<lpage>424</lpage>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>